Femasys Inc (FEMY) shareholders
FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/3072% below fair value
$1.42+0.02 (+1.43%)
Close on Nov 13, 2026Market cap $11.89MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24.7%
2M of 8M shares
Institutional holders
18
4 new, 21 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $134.00K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 4,932,825 | 7.87% | 13G (passive) | Mar 17, 2026 |
| Alumni Capital GP LLC Joint filing with Alumni Capital LP (9.99%), Ashkan Mapar (9.99%) | 4,773,579 | 9.99% | 13G (passive) | Sep 4, 2025 |
| Rosalind Master Fund L.P. Joint filing with Rosalind Advisors, Inc. (9.90%), Salamon Steven A J (9.90%) and 1 more | 4,687,500 | 9.90% | 13G (passive) | Aug 10, 2026 |
| Dauntless Investment Group, LLC | 4,395,996 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Chernett Jorey | 3,034,335 | 9.30% | 13G (passive) amendment | Jun 30, 2025 |
| Nantahala Capital Partners Limited Partnership Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%) and 1 more | 803,038 | 9.99% | 13D (active) | Aug 10, 2026 |
| Stonepine Capital Management, LLC Joint filing with Stonepine Capital, L.P. (7.20%), Stonepine GP, LLC (7.20%) and 1 more | 625,000 | 7.20% | 13G (passive) | Aug 10, 2026 |
| Ryan M. Lane Joint filing with Empery Asset Management, LP (5.60%) | 468,750 | 5.60% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FEMY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 1,867,987 | 22.30% | $7.81M | +1,566,335 | 6.13% |
| Vanguard Capital Management LLC | 62,232 | 0.74% | $260.13K | +398 | 0.00% |
| Jane Street Group, LLC | 52,511 | 0.63% | $219.50K | +50,897 | 0.00% |
| Geode Capital Management, LLC | 30,920 | 0.37% | $129.25K | −149 | 0.00% |
| UBS Group AG | 18,777 | 0.22% | $78.49K | +15,681 | 0.00% |
| Citadel Advisors LLC | 16,921 | 0.20% | $70.73K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 12,492 | 0.15% | $52.22K | −2 | 0.00% |
| Osaic Holdings, Inc. | 2,397 | 0.03% | $10.02K | −1 | 0.00% |
| BlackRock, Inc. | 1,784 | 0.02% | $7.46K | −7,141 | 0.00% |
| IFP Advisors, Inc | 1,050 | 0.01% | $515 | +1,000 | 0.00% |
| Northwestern Mutual Wealth Management Co | 1,000 | 0.01% | $4.18K | – | 0.00% |
| SRS Capital Advisors, Inc. | 900 | 0.01% | $3.76K | New | 0.00% |
| Whittier Trust Co Of Nevada Inc | 794 | 0.01% | $3.07K | – | 0.00% |
| CX Institutional | 750 | 0.01% | $3.00K | – | 0.00% |
| Trust Co Of Toledo NA /Oh/ | 87 | 0.00% | $364 | −1 | 0.00% |
| Barclays PLC | 8 | 0.00% | $33 | New | 0.00% |
| SBI Securities Co., Ltd. | 7 | 0.00% | $29 | −1 | 0.00% |
| Morgan Stanley | 3 | 0.00% | $13 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 2M | 24.7% | 4 / 5 | 6 / 21 | 2M | 0M |
| Q1 2026 | 36 | 0M | 5.7% | 9 / 8 | 6 / 9 | 0M | 0M |
| Q4 2025 | 38 | 0M | 5.6% | 13 / 7 | 4 / 7 | 0M | 0M |
| Q3 2025 | 32 | 0M | 2.2% | 5 / 8 | 5 / 9 | 0M | 0M |
| Q2 2025 | 36 | 0M | 3.2% | 8 / 10 | 4 / 2 | 0M | 0M |
| Q1 2025 | 30 | 0M | 2.3% | 4 / 9 | 2 / 3 | 0M | 0M |
| Q4 2024 | 29 | 0M | 1.4% | 6 / 3 | 6 / 4 | 0M | 0M |
| Q3 2024 | 27 | 0M | 1.0% | 4 / 2 | 2 / 4 | 0M | 0M |
| Q2 2024 | 28 | 0M | 1.0% | 8 / 6 | 2 / 3 | 0M | 0M |
| Q1 2024 | 23 | 0M | 0.9% | 2 / 7 | 3 / 3 | 0M | 0M |
| Q4 2023 | 24 | 0M | 0.9% | 6 / 8 | 4 / 10 | 0M | 0M |
| Q3 2023 | 28 | 0M | 1.0% | 11 / 6 | 6 / 5 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
10 funds held FEMY in Q1 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of FEMY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 34,296 | 0.41% | $143.36K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 27,936 | 0.33% | $116.77K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -465 | -0.01% | -$1.94K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kathy Lee-Sepsick | Chief Executive Officer, Director | 87,848 | 1.05% | Aug 11, 2026 |
| Dov Elefant | Chief Financial Officer | 15,625 | 0.19% | Aug 11, 2026 |
| Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | 1,411 | 0.02% | Aug 11, 2026 |
| John Charles Canning | Chief Operating Officer | 4,375 | 0.05% | Aug 11, 2026 |
| Jeremy Alexander Sipos | Chief Technology Officer | 3,125 | 0.04% | Aug 11, 2026 |
| Kelley Stinson Nicholas | Chief Commercial Officer | 125 | 0.00% | Jul 1, 2025 |
| Daniel Scott Currie | Chief Operating Officer | 109,240 | 1.30% | Jun 4, 2025 |
| Christine E. Thomas | Chief Reg & Clinical Officer | – | – | Jan 30, 2025 |
| John Hunnewell Moorhead Jr | Director | – | – | Nov 5, 2026 |
| Kenneth D. Eichenbaum | Director | 25,010 | 0.30% | Aug 11, 2026 |
| Charles Larsen | Director | 56 | 0.00% | Aug 11, 2026 |
| Edward R. Uzialko | Director | 1,217,406 | 14.54% | Aug 11, 2026 |
| Alistair Milnes | Director | – | – | Aug 11, 2026 |
| Joshua Silverman | Director | – | – | Mar 18, 2026 |
| PharmaCyte Biotech, Inc. | 10% owner | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dov Elefant Chief Financial Officer | Aug 7, 2026 | Buy | +15,625 | $3.20 | $50.00K | 15,625 |
| Jeffrey Gerald Mifek Chief Clinical-Medical Affairs | Aug 7, 2026 | Buy | +3,125 | $3.20 | $10.00K | 3,125 |
| Jeremy Alexander Sipos Chief Technology Officer | Aug 7, 2026 | Buy | +3,125 | $3.20 | $10.00K | 3,125 |
| Kathy Lee-Sepsick Chief Executive Officer, Director | Aug 7, 2026 | Buy | +15,625 | $3.20 | $50.00K | 15,625 |
| John Charles Canning Chief Operating Officer | Aug 7, 2026 | Buy | +4,375 | $3.20 | $14.00K | 4,375 |
| Dov Elefant Chief Financial Officer | Aug 27, 2025 | Discretionary | +38,828 | – | – | 58,436 |
| Kathy Lee-Sepsick Chief Executive Officer, Director | Aug 27, 2025 | Discretionary | +48,535 | – | – | 360,627 |
| Charles Larsen Director | Jun 2, 2025 | Discretionary | +24,510 | $1.02 | $25.00K | 56 |
| Dov Elefant Chief Financial Officer | Jun 2, 2025 | Discretionary | +19,608 | $1.02 | $20.00K | 19,608 |
| Kathy Lee-Sepsick Chief Executive Officer, Director | Jun 2, 2025 | Discretionary | +34,314 | $1.02 | $35.00K | 312,092 |
| Daniel Scott Currie Chief Operating Officer | Jun 2, 2025 | Discretionary | +19,608 | $1.02 | $20.00K | 86,275 |
| William Benson Witte Director | Dec 15, 2021 | Other | +12,191 | – | – | 12,191 |
| John Dyett Director | Dec 15, 2021 | Other | −3,219,795 | – | – | 0 |
| John Dyett Director | Dec 15, 2021 | Other | +175,635 | – | – | 290,344 |
| John Dyett Director, 10% owner | Jun 23, 2021 | Buy | +1,000 | $9.95 | $9.95K | 114,709 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Conversion | +63,709 | – | – | 113,709 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Buy | +40,000 | $13.00 | $520.00K | 50,000 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Conversion | +2,271,453 | – | – | 3,219,795 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Conversion | +948,342 | – | – | 948,342 |
| John Q. Adams JR Director | Jun 22, 2021 | Conversion | +91,245 | – | – | 131,245 |
| John Q. Adams JR Director | Jun 22, 2021 | Conversion | +108,693 | – | – | 239,938 |
| John Q. Adams JR Director | Jun 22, 2021 | Buy | +40,000 | $13.00 | $520.00K | 40,000 |
| Edward R. Uzialko Director | Jun 22, 2021 | Conversion | +1,059,445 | – | – | 1,187,231 |
| Edward R. Uzialko Director | Jun 22, 2021 | Conversion | +30,175 | – | – | 30,175 |
| Edward R. Uzialko Director | Jun 22, 2021 | Buy | +100,000 | $13.00 | $1.30M | 127,786 |
| Charles Larsen Director | Jun 22, 2021 | Conversion | +10,587 | – | – | 17,587 |
| Charles Larsen Director | Jun 22, 2021 | Buy | +7,000 | $13.00 | $91.00K | 7,000 |
| John Dyett Director, 10% owner | Jun 18, 2021 | Buy | +10,000 | $12.88 | $128.80K | 10,000 |
| John Dyett Director, 10% owner | Jun 18, 2021 | Buy | +2,500 | $13.18 | $32.95K | 2,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
4.19%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-70.0%
From 0M shares
Short volume, 20 days
30.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Femasys's stock actually held short. Settlement fails (shares not delivered on time) peaked at 447,433 shares on Aug 20, 2026 over the last 90 days.
See a number that looks wrong?